全文获取类型
收费全文 | 2647262篇 |
免费 | 196194篇 |
国内免费 | 4980篇 |
专业分类
耳鼻咽喉 | 34933篇 |
儿科学 | 87268篇 |
妇产科学 | 72908篇 |
基础医学 | 382271篇 |
口腔科学 | 76542篇 |
临床医学 | 242403篇 |
内科学 | 514356篇 |
皮肤病学 | 59380篇 |
神经病学 | 208565篇 |
特种医学 | 98806篇 |
外国民族医学 | 518篇 |
外科学 | 390086篇 |
综合类 | 59850篇 |
现状与发展 | 6篇 |
一般理论 | 1044篇 |
预防医学 | 208140篇 |
眼科学 | 62295篇 |
药学 | 194356篇 |
12篇 | |
中国医学 | 5872篇 |
肿瘤学 | 148825篇 |
出版年
2019年 | 20919篇 |
2018年 | 29561篇 |
2017年 | 22426篇 |
2016年 | 24665篇 |
2015年 | 28242篇 |
2014年 | 39255篇 |
2013年 | 58481篇 |
2012年 | 80591篇 |
2011年 | 85271篇 |
2010年 | 50114篇 |
2009年 | 47318篇 |
2008年 | 79798篇 |
2007年 | 84935篇 |
2006年 | 85223篇 |
2005年 | 82053篇 |
2004年 | 79140篇 |
2003年 | 75518篇 |
2002年 | 73074篇 |
2001年 | 128322篇 |
2000年 | 131246篇 |
1999年 | 109515篇 |
1998年 | 29821篇 |
1997年 | 26420篇 |
1996年 | 26708篇 |
1995年 | 25440篇 |
1994年 | 23501篇 |
1993年 | 21841篇 |
1992年 | 84340篇 |
1991年 | 82100篇 |
1990年 | 79188篇 |
1989年 | 76558篇 |
1988年 | 70177篇 |
1987年 | 68718篇 |
1986年 | 65075篇 |
1985年 | 61526篇 |
1984年 | 45980篇 |
1983年 | 39601篇 |
1982年 | 22838篇 |
1979年 | 42072篇 |
1978年 | 29849篇 |
1977年 | 25249篇 |
1976年 | 23527篇 |
1975年 | 25018篇 |
1974年 | 30415篇 |
1973年 | 29660篇 |
1972年 | 27690篇 |
1971年 | 25773篇 |
1970年 | 24204篇 |
1969年 | 22738篇 |
1968年 | 21188篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
22.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
23.
24.
Janitz Amanda E. Schraw Jeremy M. Xu Chao Lupo Philip J. 《Cancer causes & control : CCC》2022,33(3):483-488
Cancer Causes & Control - Congenital malformations are strong risk factors for childhood cancer. Our objective was to determine whether cancer survival differs by birth defect status among... 相似文献
25.
Clinical & Experimental Metastasis - 相似文献
26.
27.
Byrne Emma Abel Stephen Yu Alexander Shepard Matthew Karlovits Stephen M. Wegner Rodney E. 《Journal of neuro-oncology》2022,157(1):197-205
Journal of Neuro-Oncology - Adjuvant radiation is often used in patients with low grade gliomas with high-risk characteristics with a recommended dose of 45–54 Gy. We used the... 相似文献
28.
29.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献
30.